BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.
In the letter, Kenneth Londoner, Chairman & CEO of BioSig, states “BioSig’s capacity for innovation is stronger than ever, and to our knowledge, our opportunities for sustainable growth are achievable…. We expect to deliver significant progress in the year ahead.”
Topics discussed in the letter include:
- The latest PURE EP™ software features and functionality that, to our knowledge, no other intracardiac signaling technology provides.
- Data demonstrating BioSig’s capacity to drive clinical excellence.
- Research and development for an artificial intelligence (AI) medical device platform.
- Robust intellectual property and manufacturing upgrade.
- Fundraising and capital allocation.
- Vision for the future and commitment to shareholders.
To read the letter in its entirety, please visit ir.biosig.com/presentations.
About BioSig Technologies, Inc.
BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform technology is addressing some of healthcare’s biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed; (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55 Greens Farms Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
